Plasma protein metabolism disease
MONDO:0002273An inherited metabolic disorder that involves plasma protein metabolism malfunction.
47 clinical trials for this condition and its sub-types, 0 tagged with Plasma protein metabolism disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Plasma protein metabolism disease
-
Alpha 1-antitrypsin deficiency 44 trials
-
Monoclonal paraproteinemia disease 2 trials
-
RNA editing drug WVE-006 enters first human safety trial
Disease control CompletedThis Phase 1 trial tested WVE-006, an RNA editing drug, in 47 healthy volunteers to see if it is safe and how the body processes it. The study is the first step toward a possible treatment for Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver disea…
Phase 1 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot method for Alpha-1 lung disease shows promise in early trial
Disease control CompletedThis study tested a new way to give Alpha-1 protein therapy by injecting it under the skin instead of into a vein. Seventeen adults with Alpha-1 Antitrypsin Deficiency received either a low or high dose weekly for eight weeks. The main goal was to check safety and how the drug mo…
Phase 1/2 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New shot aims to stop liver damage in rare genetic disease
Disease control CompletedThis Phase 2 study tested a drug called fazirsiran in 40 adults with Alpha-1 antitrypsin deficiency, a genetic condition that can cause liver disease. The drug is designed to lower levels of a harmful protein (Z-AAT) in the blood. Researchers measured safety and how much the prot…
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug targets liver damage in rare genetic disease
Disease control CompletedThis study tested a drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The drug aims to reduce harmful protein buildup in the liver. Researchers measured changes in liver protein levels and safety over 24 to 4…
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a smartphone breathing game help Alpha-1 patients breathe easier?
Symptom relief CompletedThis study tested a simple, home-based breathing technique called the Active Cycle of Breathing Technique (ACBT) with augmented reality support in 50 adults with Alpha-1 antitrypsin deficiency. Participants did the breathing exercises twice daily and walked at least 5000 steps pe…
Sponsor: University of Parma • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Healthy volunteers help test new Alpha-1 drug safety
Knowledge-focused CompletedThis early-stage study tested the safety and how the body processes a new drug called ARO-AAT in 45 healthy adults. The goal was to see if the drug is safe and to measure its levels in the blood. This research is a first step toward a possible treatment for Alpha-1 Antitrypsin De…
Phase 1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Do vaccines work as well in people with weak immune systems? new study investigates
Knowledge-focused CompletedThis study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…
Phase 4 • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can genes predict liver risk in kids with rare disorder?
Knowledge-focused CompletedThis study looks at genetic differences in children with alpha-1 antitrypsin deficiency, a rare inherited condition that can cause liver disease. Researchers will compare gene patterns between children who develop liver problems and those who do not, using blood samples from abou…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC